婴幼儿血管瘤临床治疗的研究现状
Research Status of Clinical Treatment of Infantile Hemangioma
DOI: 10.12677/ACM.2023.133449, PDF,   
作者: 单玮碧, 朱雅琳*:新疆医科大学第一附属医院皮肤科,新疆 乌鲁木齐
关键词: 婴幼儿血管瘤局部治疗系统治疗联合治疗Infantile Hemangioma Local Treatment System Treatment Combined Treatment
摘要: 婴幼儿血管瘤(Infantile Hemangioma, IH)是血管内皮细胞及其周围组织的良性增殖性疾病,是婴幼儿时期最常见的良性血管肿瘤。尽管IH是良性的,但仍有部分IH持续进展造成很多可能的不良后果,例如:溃疡、功能影响、毁容、合并其他疾病甚至可能危及生命,因此正确的评估及治疗对患者后期的转归尤为重要。IH的治疗选择在过去的十年发生了巨大的变化,越来越多的国内外学者提出了个体化及联合治疗方案。故本文探讨了IH的多种治疗方法及其转归情况。
Abstract: Infantile hemangioma (IH) is a benign proliferative disease of vascular endothelial cells and sur-rounding tissues, which is the most common benign vascular tumor in infants. Although IH is be-nign, there are still some of it will continue to progress and cause plenty of possible adverse conse-quences, such as ulcer, functional impact, disfigurement, other complications and sometimes it could even be life-threatening. Therefore, appropriate assessment and treatment are particularly important to the prognosis of patients in the later stage. The choice of IH treatment has changed dramatically in the past decade, while an increasing number of domestic and foreign scholars pro-posed individualized and combined treatment protocols. Hence, this paper discusses various treatments of IH and the subsequent outcomes of patients in different therapeutic schedules.
文章引用:单玮碧, 朱雅琳. 婴幼儿血管瘤临床治疗的研究现状[J]. 临床医学进展, 2023, 13(3): 3155-3162. https://doi.org/10.12677/ACM.2023.133449

参考文献

[1] Mansfield, S.A., Williams, R.F. and Iacobas, I. (2020) Vascular Tumors. Seminars in Pediatric Surgery, 29, Article ID: 150975. [Google Scholar] [CrossRef] [PubMed]
[2] 邹运, 陈辉, 林晓曦. ISSVA血管瘤和脉管畸形新分类(2018版) [J]. 中国美容整形外科杂志, 2018, 29(12): 711-713+771-780.
[3] Briones, M. and Adams, D. (2021) Neonatal Vascular Tumors. Clinics in Perinatology, 48, 181-198. [Google Scholar] [CrossRef] [PubMed]
[4] Rodríguez Bandera, A.I., Sebaratnam, D.F., Wargon, O. and Wong, L.-C.F. (2021) MBBS Hons Mab, Owhm C, et al. Infantile Hemangioma. Part 1: Epidemiology, Pathogenesis, Clinical Presentation and Assessment. Journal of the American Academy of Dermatology, 85, 1379-1392. [Google Scholar] [CrossRef] [PubMed]
[5] Léauté-Labrèze, C., Harper, J.I. and Hoeger, P.H. (2017) Infantile Haemangioma. Lancet, 390, 85-94. [Google Scholar] [CrossRef
[6] Sebaratnam, D.F., Rodríguez Bandera, A.I., Wong, L.-C.F. and Wargon, O. (2021) Infantile Hemangioma. Part 2: Management. Journal of the American Academy of Dermatology, 85, 1395-1404. [Google Scholar] [CrossRef] [PubMed]
[7] Cîrstoveanu, C., Bizubac, A.M., Mustea, C., et al. (2021) Antipro-liferative Therapy with Sirolimus and Propranolol for Congenital Vascular Anomalies in Newborns (Case Reports). Ex-perimental and Therapeutic Medicine, 22, Article No. 1097. [Google Scholar] [CrossRef] [PubMed]
[8] Xu, M.-N., Zhang, M., Xu, Y., Wang, M. and Yuan, S.-M. (2018) Individualized Treatment for Infantile Hemangioma. Journal of Craniofacial Surgery, 29, 1876-1879. [Google Scholar] [CrossRef
[9] Filoni, A., Ambrogio, F., De Marco, A., Pacific, A. and Bonamonte, D. (2021) Topical Beta-Blockers in Dermatologic Therapy. Dermatologic Therapy, 34, e15016. [Google Scholar] [CrossRef] [PubMed]
[10] Lin, Z., Zhang, B., Yu, Z. and Li, H. (2020) The Effectiveness and Safety of Topical Β-Receptor Blocker in Treating Superficial Infantile Haemangiomas: A Meta-Analysis Including 20 Studies. British Journal of Clinical Pharmacology, 86, 199-209. [Google Scholar] [CrossRef] [PubMed]
[11] Muñoz-Garza, F.Z., Ríos, M., Roé-Crespo, E., et al. (2021) Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial. JAMA Dermatology, 157, 583-587. [Google Scholar] [CrossRef] [PubMed]
[12] Zheng, L. and Li, Y. (2018) Effect of Topical Timolol on Response Rate and Adverse Events in Infantile Hemangioma: A Me-ta-Analysis. Archives of Dermatological Research, 310, 261-269. [Google Scholar] [CrossRef] [PubMed]
[13] Danarti, R., Ariwibowo, L., Radiono, S. and Budiyanto, A. (2016) Topical Timolol Maleate 0.5% for Infantile Hemangioma: Its Effectiveness Compared to Ultrapotent Topical Corticoster-oids—A Single-Center Experience of 278 Cases. Dermatology, 232, 566-571. [Google Scholar] [CrossRef] [PubMed]
[14] Zhang, J.-Y., Lan, S.-J., Liu, M., et al. (2021) Topical Timolol Combined Intralesional Injection of Diprospan in the Treatment of Elevated Localized Mixed Infantile Hemangiomas and a Discus-sion for Proper Timing for Injection. Journal of Craniofacial Surgery, 32, 988-990. [Google Scholar] [CrossRef
[15] Chinnadurai, S., Fonnesbeck, C., Snyder, K.M., et al. (2016) Pharmacologic Interventions for Infantile Hemangioma: A Meta-Analysis. Pediatrics, 137, e20153896. [Google Scholar] [CrossRef] [PubMed]
[16] Novoa, M., Baselga, E., Beltran, S., et al. (2018) Interventions for In-fantile Haemangiomas of the Skin. Cochrane Database of Systematic Reviews, 4, Article ID: CD006545. [Google Scholar] [CrossRef
[17] Zhang, L., Zheng, J.W. and Yuan, W. (2015) Treatment of Alarming Head and Neck Infantile Hemangiomas with Interferon-α2a: A Clinical Study in Eleven Consecutive Patients. Drug Design, Development and Therapy, 9, 723-727. [Google Scholar] [CrossRef
[18] Chai, Y., Zhou, Z., Song, J., et al. (2019) Safety of Intralesional Injec-tion of Lauromacrogol Combined with Triamcinolone for Infantile Hemangiomas. The Journal of Dermatology, 46, 770-776. [Google Scholar] [CrossRef] [PubMed]
[19] Sabry, H.H., Sorour, N.E. and Akl, E.M. (2020) Intralesional Injec-tion of Bevacizumab versus Triamcinolone Acetonide in Infantile Hemangioma. Journal of Dermatological Treatment, 31, 279-284. [Google Scholar] [CrossRef] [PubMed]
[20] Hutchinson, A.K., Kraker, R.T., Pineles, S.L., et al. (2019) The Use of β-Blockers for the Treatment of Periocular Hemangiomas in Infants. Ophthalmology, 126, 146-155. [Google Scholar] [CrossRef] [PubMed]
[21] Püttgen, K., Lucky, A., et al. (2016) Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics, 138, e20160355. [Google Scholar] [CrossRef] [PubMed]
[22] Pandey, V., Tiwari, P., Imran, M., et al. (2021) Adverse Drug Reac-tions Following Propranolol in Infantile Hemangioma. Indian Pediatrics, 58, 753-755. [Google Scholar] [CrossRef
[23] Li, G., Xu, D.-P., Tong, S., et al. (2016) Oral Propranolol with Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions. Journal of Cra-niofacial Surgery, 27, 56-60. [Google Scholar] [CrossRef
[24] Knöpfel, N., Oesch, V., Theiler, M., Szello, P. and Weibel, L. (2020) Rebound of Involuted Infantile Hemangioma after Administration of Salbutamol. Pediatrics, 145, e20191942. [Google Scholar] [CrossRef] [PubMed]
[25] Fernando, S.J., Leitenberger, S., Majerus, M., Krol, A. and MacAr-thur, C.J. (2016) Use of Intravenous Propranolol for Control of a Large Cervicofacial Hemangioma in a Critically Ill Ne-onate. International Journal of Pediatric Otorhinolaryngology, 84, 52-54. [Google Scholar] [CrossRef] [PubMed]
[26] Bennett, M.L., Fleischer Jr., A.B., Chamlin, S.L. and Frieden, I.J. (2001) Oral Corticosteroid Use Is Effective for Cutaneous Hemangiomas: An Evidence-Based Evaluation. Archives of Dermatology, 137, 1208-1213. [Google Scholar] [CrossRef] [PubMed]
[27] Satterfield, K.R. and Chambers, C.B. (2019) Current Treatment and Management of Infantile Hemangiomas. Survey of Ophthalmology, 64, 608-618. [Google Scholar] [CrossRef] [PubMed]
[28] Al-Haddad, C., El Salloukh, N.A. and El Moussawi, Z. (2019) β-Blockers in the Treatment of Periocular Infantile Hemangioma. Current Opinion in Ophthalmology, 30, 319-325. [Google Scholar] [CrossRef
[29] Polites, S.F., Watanabe, M., Crafton, T., et al. (2019) Surgical Resection of Infantile Hemangiomas Following Medical Treatment with Propranolol versus Corticoster-oids. Journal of Pediatric Surgery, 54, 740-743. [Google Scholar] [CrossRef] [PubMed]
[30] Polites, S.F., Rodrigue, B.B., Chute, C., Hammill, A. and Dasgupta, R. (2018) Propranolol versus Steroids for the Treatment of Ulcerated Infantile Hemangiomas. Pediatric Blood & Cancer, 65, e27280. [Google Scholar] [CrossRef] [PubMed]
[31] Zaher, H., Rasheed, H., El-Komy, M.M., et al. (2016) Propranolol versus Captopril in the Treatment of Infantile Hemangioma (IH): A Randomized Controlled Trial. The Journal of the American Academy of Dermatology, 74, 499-505. [Google Scholar] [CrossRef] [PubMed]
[32] Cho, Y.J., Kwon, H., Kwon, Y.J., et al. (2021) Effects of Sirolimus in the Treatment of Unresectable Infantile Hemangioma and Vascular Malformations in Children: A Single-Center Expe-rience. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 9, 1488-1494. [Google Scholar] [CrossRef] [PubMed]
[33] Jin, W.-W., Tong, Y., Wu, J.-M., Quan, H.-H. and Gao, Y. (2020) Observation on the Effects of 595-nm Pulsed Dye laser and 755-nm Long-Pulsed Alexandrite Laser on Sequential Ther-apy of Infantile Hemangioma. Journal of Cosmetic and Laser Therapy, 22, 159-164. [Google Scholar] [CrossRef] [PubMed]
[34] Filaj, V., Jorgaqi, E. and Byzhyti, M. (2021) Our Experience in the Treatment of Hemangioma with Intense Pulsed Light Laser: A 10 Year Study in Albania. Dermatologic Therapy, 34, e14880. [Google Scholar] [CrossRef] [PubMed]
[35] Ying, H., Zou, Y., Yu, W., et al. (2017) Prospective, Open-Label, Rater-Blinded and Self-Controlled Pilot Study of the Treatment of Proliferating Superficial Infantile Heman-giomas with 0.5% Topical Timolol Cream versus 595-nm Pulsed Dye Laser. The Journal of Dermatology, 44, 660-665. [Google Scholar] [CrossRef] [PubMed]
[36] Chelleri, C., Monzani, N.A., Gelmetti, C., et al. (2020) Residual Le-sions after Pharmacological and Dye-Laser Treatment of Infantile Hemangiomas: Critical Review of 432 Cases. Lasers in Surgery and Medicine, 52, 597-603. [Google Scholar] [CrossRef] [PubMed]
[37] Bleve, C., Conighi, M.L., Valerio, E., et al. (2022) Surgical Management of Large Scalp Infantile Hemangioma in 30-Month-Old Infant. La Pediatria Medica E Chirurgica, 44, Article No. 279. [Google Scholar] [CrossRef] [PubMed]
[38] Men, C.J., Ediriwickrema, L.S., Paik, J.S., et al. (2020) Surgical Inter-vention of Periocular Infantile Hemangiomas in the Era of β-Blockers. Ophthalmic Plastic and Reconstructive Surgery, 36, 70-73. [Google Scholar] [CrossRef
[39] Cheng, J., Liu, B. and Lee, H.-J. (2019) Outcomes of Surgi-cal Treatment for Hemangiomas. Pediatric Dermatology, 36, 207-212. [Google Scholar] [CrossRef] [PubMed]
[40] 庞筱安, 韦智晓, 李俊红, 等. 90Sr敷贴在皮肤血管瘤治疗中的应用[J]. 中华核医学与分子影像杂志, 2021, 41(7): 435-437.